Cure My Disease

Don't miss your cure!

 Log in / Sign up

New filler study shows promise for Wrinkle-Free, fuller faces

NCT ID NCT07301619

Symptom relief Sponsor: i+Med S.Coop. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested BtHCROSS, a gel-like filler made from hyaluronic acid, to see if it safely restores facial volume and reduces wrinkles. 203 adults aged 30 to 70 received one treatment and were followed for 9 months. Doctors measured improvements in skin appearance and tracked any side effects. The results support the product's use for cosmetic facial rejuvenation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

203 people

The number who actually took part.

Started

Apr 2022

Finished

Feb 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female, aged between 30 and 70 years. * Individuals showing mild to moderate signs of facial skin aging (such as loss of brightness, hydration, and/or firmness). * Sufficient willingness and ability, as judged by the investigator, to complete the study questionnaires. Exclusion Criteria: * Pregnant or breastfeeding women. * Known allergy or sensitivity to hyaluronic acid or any other ingredient in the product. * Individuals who have undergone any wrinkle correction or rejuvenation procedures in the past 6 months or during the study (e.g., radiofrequency, electrotherapy, botulinum toxin, thread lifts, or laser techniques). * Autoimmune or inflammatory diseases, or any condition affecting skin health that could interfere with the treatment. * History of any illness or infection in the injection area during the study. * Lymphatic and/or vascular disorders. * Individuals with unrealistic expectations about the treatment outcomes. * Previous facial surgery. * Active infection in the treatment area. * Blood coagulation disorders. Subjects on anticoagulant therapy are excluded, even without a diagnosed coagulation issue, unless cleared by their prescribing specialist. * Subjects with unrealistic expectations regarding the likely outcomes of the treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aesthetics procedure are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aesthetics procedure

Contacts and locations

Locations

  • Complutense Medical Center (Virtus Group)

    Madrid, Madrid, 28805, Spain